[go: up one dir, main page]

EP3468539A4 - Administration à libération prolongée par voie parentérale de systèmes de dispersion de carvédilol - Google Patents

Administration à libération prolongée par voie parentérale de systèmes de dispersion de carvédilol Download PDF

Info

Publication number
EP3468539A4
EP3468539A4 EP17813962.2A EP17813962A EP3468539A4 EP 3468539 A4 EP3468539 A4 EP 3468539A4 EP 17813962 A EP17813962 A EP 17813962A EP 3468539 A4 EP3468539 A4 EP 3468539A4
Authority
EP
European Patent Office
Prior art keywords
carvedilol
release delivery
disperse systems
parenteral sustained
parenteral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP17813962.2A
Other languages
German (de)
English (en)
Other versions
EP3468539A1 (fr
Inventor
Vera Ivanova
Kaoru Maeda
Wan Wang
Dongwei GUO
Jingjun Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ascendia Pharmaceuticals LLC
Original Assignee
Ascendia Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascendia Pharmaceuticals LLC filed Critical Ascendia Pharmaceuticals LLC
Publication of EP3468539A1 publication Critical patent/EP3468539A1/fr
Publication of EP3468539A4 publication Critical patent/EP3468539A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP17813962.2A 2016-06-13 2017-06-13 Administration à libération prolongée par voie parentérale de systèmes de dispersion de carvédilol Pending EP3468539A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662349390P 2016-06-13 2016-06-13
PCT/US2017/037311 WO2017218576A1 (fr) 2016-06-13 2017-06-13 Administration à libération prolongée par voie parentérale de systèmes de dispersion de carvédilol

Publications (2)

Publication Number Publication Date
EP3468539A1 EP3468539A1 (fr) 2019-04-17
EP3468539A4 true EP3468539A4 (fr) 2020-01-15

Family

ID=60573487

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17813962.2A Pending EP3468539A4 (fr) 2016-06-13 2017-06-13 Administration à libération prolongée par voie parentérale de systèmes de dispersion de carvédilol

Country Status (8)

Country Link
US (2) US20170354592A1 (fr)
EP (1) EP3468539A4 (fr)
JP (3) JP2019521979A (fr)
KR (1) KR102474392B1 (fr)
CN (1) CN110381929A (fr)
BR (1) BR112018075984A2 (fr)
CA (1) CA3027368A1 (fr)
WO (1) WO2017218576A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018075984A2 (pt) 2016-06-13 2019-04-02 Ascendia Pharmaceuticals, Llc composição de distribuição de fármaco parenteral para liberação sustentada
KR20220074910A (ko) * 2019-10-01 2022-06-03 에보닉 코포레이션 생체-재흡수성 폴리에스테르를 포함하는 분말 형태의 나노입자 제조 방법
JP7600528B2 (ja) * 2020-03-16 2024-12-17 株式会社リコー 粒子の製造方法
CN114159405B (zh) * 2020-09-10 2023-06-23 上海中医药大学 一种在胃肠道内稳定的口服纳米粒子及其制备方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996024348A2 (fr) * 1995-02-08 1996-08-15 Boehringer Mannheim Pharmaceuticals Corporation Utilisation de composes de carbazole pour le traitement de l'insuffisance cardiaque congestive
US5643939A (en) * 1993-03-05 1997-07-01 Boehringer Mannheim Pharmaceutical Corporation-Smithkline Beecham Corporation Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation
WO2001074356A1 (fr) * 2000-04-03 2001-10-11 F. Hoffmann-La Roche Ag Solutions concentrees de carvedilol
WO2005051322A2 (fr) * 2003-11-25 2005-06-09 Sb Pharmco Puerto Rico Inc. Base libre de carvedilol, ses sels, formes anhydres ou solvates, compositions pharmaceutiques correspondantes, formulations a liberation controlee, et procedes de traitement ou d'administration
US20070202180A1 (en) * 2006-02-28 2007-08-30 Elan Pharma International Limited Nanoparticulate carverdilol formulations

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9203808A (es) 1987-03-05 1992-07-01 Liposome Co Inc Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
US5576016A (en) 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
US5891467A (en) * 1997-01-31 1999-04-06 Depotech Corporation Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes
EP1068509A4 (fr) * 1998-03-30 2005-05-25 Bioshaf Cytometre de flux pour l'analyse des facteurs generaux de diagnostic dans les cellules et les fluides biologiques
US6664284B2 (en) 1998-07-23 2003-12-16 Roche Diagnostics Gmbh Stabilized carvedilol injection solution
WO2000012110A2 (fr) 1998-08-26 2000-03-09 Queen's University At Kingston Methodes de remodelisation des voies neuronales et cardiovasculaires
US7235237B2 (en) * 1999-10-29 2007-06-26 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
AU2002337815A1 (en) * 2001-10-05 2003-04-22 Suwalee Chandrkrachang Active agents using liposome beads
US20040224012A1 (en) 2001-10-05 2004-11-11 Pichit Suvanprakorn Topical application and methods for administration of active agents using liposome macro-beads
EP1585504A4 (fr) 2002-11-06 2009-07-15 Azaya Therapeutics Inc Preparations liposomales d'agents pharmaceutiques stabilisees par des proteines
US20050143378A1 (en) 2003-12-29 2005-06-30 Yun Anthony J. Treatment of conditions through pharmacological modulation of the autonomic nervous system
US8569277B2 (en) 2004-08-11 2013-10-29 Palo Alto Investors Methods of treating a subject for a condition
US8691877B2 (en) 2004-10-15 2014-04-08 Palo Alto Investors Methods and compositions for treating a disease condition in a subject
US20090148498A1 (en) * 2007-05-14 2009-06-11 Sustained Nano Systems Llc Controlled release implantable dispensing device and method
JP2011518881A (ja) 2008-04-28 2011-06-30 ゾゲニクス インコーポレーティッド 片頭痛の治療のための製剤
JP2014510045A (ja) * 2011-02-08 2014-04-24 ハロザイム インコーポレイテッド ヒアルロナン分解酵素の組成物および脂質製剤ならびに良性前立腺肥大症の治療のためのその使用
JP2014506922A (ja) 2011-03-01 2014-03-20 ティーオー − ビービービー ホールディング ベスローテン フェンノートシャップ 難水溶性物質の高度なアクティブリポソームローディング
EP2877159B8 (fr) * 2012-07-27 2018-02-14 Izumi Technology, LLC. Compositions inhibitrices d'écoulement et méthodes de traitement à l'aide celles-ci
BR112018075984A2 (pt) 2016-06-13 2019-04-02 Ascendia Pharmaceuticals, Llc composição de distribuição de fármaco parenteral para liberação sustentada

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643939A (en) * 1993-03-05 1997-07-01 Boehringer Mannheim Pharmaceutical Corporation-Smithkline Beecham Corporation Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation
WO1996024348A2 (fr) * 1995-02-08 1996-08-15 Boehringer Mannheim Pharmaceuticals Corporation Utilisation de composes de carbazole pour le traitement de l'insuffisance cardiaque congestive
WO2001074356A1 (fr) * 2000-04-03 2001-10-11 F. Hoffmann-La Roche Ag Solutions concentrees de carvedilol
WO2005051322A2 (fr) * 2003-11-25 2005-06-09 Sb Pharmco Puerto Rico Inc. Base libre de carvedilol, ses sels, formes anhydres ou solvates, compositions pharmaceutiques correspondantes, formulations a liberation controlee, et procedes de traitement ou d'administration
US20070202180A1 (en) * 2006-02-28 2007-08-30 Elan Pharma International Limited Nanoparticulate carverdilol formulations

Also Published As

Publication number Publication date
JP2019521979A (ja) 2019-08-08
JP2022103337A (ja) 2022-07-07
EP3468539A1 (fr) 2019-04-17
WO2017218576A1 (fr) 2017-12-21
US10792244B2 (en) 2020-10-06
CN110381929A (zh) 2019-10-25
US20200000706A1 (en) 2020-01-02
KR20190109376A (ko) 2019-09-25
KR102474392B1 (ko) 2022-12-07
CA3027368A1 (fr) 2017-12-21
US20170354592A1 (en) 2017-12-14
JP2024095802A (ja) 2024-07-10
BR112018075984A2 (pt) 2019-04-02

Similar Documents

Publication Publication Date Title
EP3287400A4 (fr) Système de distribution
EP3287399A4 (fr) Système de livraison
EP3212173A4 (fr) Systèmes d'administration
GB2550451B (en) Offline peer-assisted notification delivery
EP3373908B8 (fr) Systèmes d'administration de probiotiques
EP3566686A4 (fr) Dispositif d'alimentation en médicament
EP3253357A4 (fr) Pompe pour alimentation entérale
EP3267965A4 (fr) Technologie d'administration d'exosomes
EP3338577A4 (fr) Ceinture verticale
IL274920A (en) Maytansinoid-based drug delivery systems
EP3468539A4 (fr) Administration à libération prolongée par voie parentérale de systèmes de dispersion de carvédilol
HUE057487T2 (hu) Gyógyszeradagoló rendszer
EP3162042A4 (fr) Identification de participants à un appel
EP3650484A4 (fr) Support d'administration de médicament ciblant le rein
IL275664A (en) drug delivery system
EP3217947A4 (fr) Systèmes d'administration de médicament pour les reins
EP3335406A4 (fr) Réglage du numéro de téléphone
GB201717433D0 (en) Infusion systems
HK40007313A (en) Parenteral sustained-release delivery of carvedilol disperse systems
GB201700313D0 (en) Notification system
HK40039292A (en) Maytansinoid-based drug delivery systems
HK40004386A (en) Gastric residence systems for sustained delivery of adamantane-class drugs
GB2559449B (en) Hypoallergic drug delivery system
HK40022899A (en) Drug delivery system
HK40002769A (en) Delivery system

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190108

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20191217

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 9/12 20060101ALI20191211BHEP

Ipc: A61K 9/51 20060101ALI20191211BHEP

Ipc: A61K 31/403 20060101ALI20191211BHEP

Ipc: A61K 9/50 20060101AFI20191211BHEP

Ipc: A61P 9/04 20060101ALI20191211BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40007313

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20220906